ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization

ACVRL1 drives resistance to multitarget tyrosine kinase inhibitors in colorectal cancer by promoting USP15-mediated GPX2 stabilization

Abstract Background Multitarget tyrosine kinase inhibitors (mTKIs) such as Regorafenib and Sorafenib have already been approved for the treatment of many solid tumours. However, the efficacy of mTKIs in colorectal cancer (CRC) is limited; the underlined mechanism remains largely elusive. Our study w...

Full description

Bibliographic Details
Main Authors: Xiaolin Lu, Ruiqi Liu, Yuanyu Liao, Luying Cui, Haoxiu Sun, Dongzhi Zhang, Bojun Wang, Lin Fang, Xin Guan, Yuanfei Yao, Chao Liu, Yanqiao Zhang
Format: Article
Language:English
Published: BMC 2023-09-01
Series:BMC Medicine
Subjects:
Colorectal cancer
Multitarget tyrosine kinase inhibitors
Drug resistance
Activin A receptor-like type 1
Glutathione peroxidase 2
Reactive oxygen species
Online Access:https://doi.org/10.1186/s12916-023-03066-4

Internet

https://doi.org/10.1186/s12916-023-03066-4

Similar Items